Effect of antidepressant drugs on monoamine synthesis in brain in vivo.
The activity of tryptophan and tyrosine hydroxylase were estimated in vivo by measuring the accumulation during 30 min of 5-hydroxytryptophan (5-HTP) and 3,4-dihydroxyphenylalanine (DOPA), respectively, after inhibition of aromatic amino acid decarboxylase by administration of m-hydroxybenzylhydrazine (NSD 1015) (100 mg/kg, i.p.). Whereas the activity of tyrosine hydroxylase in the dopamine-rich striatum was sensitive to haloperidol, which caused a significant increase in accumulation of DOPA, there was no effect of haloperidol in the predominantly noradrenergic frontoparietal cortex, confirming that the activity of tyrosine hydroxylase, measured in the frontoparietal cortex, is essentially localized in noradrenergic neurones. In the frontoparietal cortex of the rat the in vivo activity of tryptophan and tyrosine hydroxylase were equipotently attenuated by imipramine, while the selective blocker of the uptake of noradrenaline, desipramine and the selective blocker of the uptake of serotonin, citalopram, reduced only tyrosine or tyrosine hydroxylase respectively. Milnacipran, an antidepressant which inhibits the uptake of both monoamines to a similar extent, decreased the synthesis of both monoamines equipotently. The monoamine oxidase inhibitor, clorgyline, also reduced the synthesis of both monoamines. Thus, the in vivo inhibition of the synthesis of monoamines would appear to be mediated by an increase in synaptic concentration of monoamines, resulting from the inhibition of the uptake or catabolism of monoamines. Chronic administration of citalopram led to a significant increase of the basal synthesis of 5-hydroxytryptamine (5-HT). Milnacipran, given chronically, significantly enhanced the basal synthesis of both 5-HT and noradrenaline (NA).(ABSTRACT TRUNCATED AT 250 WORDS)
Division of Neurobiology I, Pierre Fabre Research Centre, Castres, France.
C
C
Moret
M
M
Briley
D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology*; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D015283:Citalopram / Q000494:pharmacology; D003010:Clorgyline / Q000494:pharmacology; D003521:Cyclopropanes / Q000494:pharmacology; D003891:Desipramine / Q000494:pharmacology; D004295:Dihydroxyphenylalanine / Q000096:biosynthesis*; D004305:Dose-Response Relationship, Drug; D006220:Haloperidol / Q000494:pharmacology; D006834:Hydrazines / Q000494:pharmacology; D007099:Imipramine / Q000494:pharmacology; D008297:Male; D000078764:Milnacipran; D009638:Norepinephrine / Q000096:biosynthesis; D009928:Organ Specificity; D010296:Parietal Lobe / Q000187:drug effects / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D012701:Serotonin / Q000096:biosynthesis*; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
D000928:Antidepressive Agents; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D003521:Cyclopropanes; D006834:Hydrazines; D015283:Citalopram; D012701:Serotonin; D004295:Dihydroxyphenylalanine; C004297:3-hydroxybenzylhydrazine; D014446:Tyrosine 3-Monooxygenase; D000078764:Milnacipran; D006220:Haloperidol; D003010:Clorgyline; D007099:Imipramine; D003891:Desipramine; D009638:Norepinephrine